Is AbbVie Inc. (ABBV) A Good Stock to Buy Now?

Copyright: mikkolem / 123RF Stock Photo

AbbVie Inc., a research-based biopharmaceutical company, engages successful the probe and development, manufacturing, commercializing, and merchantability of medicines and therapies worldwide. ABBV is navigating the post-Humira epoch with a diversified and increasing cause portfolio, successfully transitioning from reliance connected its erstwhile blockbuster. Humira, erstwhile the world’s bestselling cause with implicit $20 cardinal successful yearly sales, saw its U.S. patent expire successful 2023 and mislaid extortion overseas earlier, causing AbbVie’s gross to diminution temporarily.

The company, however, anticipated this eventuality and has launched a bid of caller therapies successful immunology and oncology that are already offsetting Humira’s decline. Its immunology drugs, Skyrizi and Rinvoq, present make combined income of $6.9 billion, connected way to surpass Humira’s highest performance, with guidance projecting $31 cardinal successful 2027 and $40 cardinal by 2029. Beyond these, AbbVie’s pipeline is extensive, with 20 drugs successful signifier III trials and implicit 50 successful earlier development, targeting high-demand indications specified arsenic humor cancers and Parkinson’s disease. This positions the institution for sustained maturation and important aboriginal gross streams.

Despite past headwinds from patent expirations, AbbVie’s shares person rebounded, rising implicit 20% successful 2025, reflecting the market’s designation of its palmy modulation and robust outlook. The institution besides combines maturation with beardown income, offering a $6.92 yearly dividend, representing a 3.1% yield, and maintaining a 53-year past of yearly dividend increases, averaging 12.5% maturation implicit the past decade. With its de-risked gross trajectory, expanding pipeline, and reliable currency flow, AbbVie presents an charismatic concern opportunity, blending income stableness with maturation potential, making the banal a compelling bargain for investors seeking some output and superior appreciation.

Previously, we covered a bullish thesis connected AbbVie Inc. (ABBV) by Magnus Ofstad successful May 2025, which highlighted beardown Q1 performance, Skyrizi and Rinvoq offsetting Humira’s decline, and breakthroughs successful oncology with Elahere. ABBV’s banal terms has appreciated by astir 14.7% since our coverage. @MoneyShow shares a akin presumption but emphasizes AbbVie’s post-Humira transition, expanding pipeline, and semipermanent dividend maturation arsenic halfway concern drivers.